- - -
IPPF/Tommy Trenchard

Resources

Latest resources from across the federation and our partners

Spotlight

A selection of resources from across the Federation

HIV
Resource

HIV Theory of Change

Our HIV Theory of Change is to clarify the goals and vision of IPPF’s HIV programme and to articulate the different pathways and strategies IPPF uses to contribute towards its HIV goals and vision.
IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

クリニックで順番を待つ患者たち
Resource

| 05 December 2017

Staff and volunteers remain dedicated and determined as the impact of the GGR takes effect

The continuation of many vital health services Amodefa offers in Mozambique are under threat following the reintroduction of the Global Gag Rule by the US Administration. The Global Gag Rule, or Mexico City Policy as it is formally known, stops US aid to all health programmes run by organisations who perform or counsel on abortion. The decision, which will deprive Amodefa of $2 million, 60% of its budget, will have devastating consequences for the fight against HIV in Mozambique, where an estimated 12% of the country’s nearly 30 million population are living with the virus. Photography © IPPF/Grant Lee Neuenburg

クリニックで順番を待つ患者たち
Resource

| 05 December 2017

Staff and volunteers remain dedicated and determined as the impact of the GGR takes effect

The continuation of many vital health services Amodefa offers in Mozambique are under threat following the reintroduction of the Global Gag Rule by the US Administration. The Global Gag Rule, or Mexico City Policy as it is formally known, stops US aid to all health programmes run by organisations who perform or counsel on abortion. The decision, which will deprive Amodefa of $2 million, 60% of its budget, will have devastating consequences for the fight against HIV in Mozambique, where an estimated 12% of the country’s nearly 30 million population are living with the virus. Photography © IPPF/Grant Lee Neuenburg

Young man
Resource

| 01 December 2017

The college student using music to tackle HIV stigma

Compared to many developing countries, HIV prevalence in Nepal is low. Yet there are deep and complex problems around HIV. Stigma remains a huge problem. People living with HIV say they have faced enormous discrimination, including being ostracized by their communities, bullied at school and work, and exposed to insults and even violence.   HIV services and support are central to the work of the Family Planning Association of Nepal (FPAN). Its staff and volunteers run services around the country, providing HIV counselling, education on prevention and treatment, and community home-based care services. People living with HIV are at the forefront of this work: FPAN employs thousands of community home-based care mobilisers who are themselves HIV-positive, meaning they are able to provide people with clear, sensitive and empathetic support that draws on their own experiences.    Photography © IPPF/Jon Spaull  Read Milan's story and watch the video

Young man
Resource

| 01 December 2017

The college student using music to tackle HIV stigma

Compared to many developing countries, HIV prevalence in Nepal is low. Yet there are deep and complex problems around HIV. Stigma remains a huge problem. People living with HIV say they have faced enormous discrimination, including being ostracized by their communities, bullied at school and work, and exposed to insults and even violence.   HIV services and support are central to the work of the Family Planning Association of Nepal (FPAN). Its staff and volunteers run services around the country, providing HIV counselling, education on prevention and treatment, and community home-based care services. People living with HIV are at the forefront of this work: FPAN employs thousands of community home-based care mobilisers who are themselves HIV-positive, meaning they are able to provide people with clear, sensitive and empathetic support that draws on their own experiences.    Photography © IPPF/Jon Spaull  Read Milan's story and watch the video

credits: UNFPA
Resource

| 24 September 2017

Global Sexual and Reproductive Health Package for Men and Adolescent Boys

The Global Sexual and Reproductive Health Service Package for Men and Adolescent Boys has been developed to support providers of sexual and reproductive health services. It aims to increase the range and quality of sexual and reproductive services provided that meet the specific and diverse needs of men and adolescents boys. It covers men and adolescent boys in all their diversity, and takes a positive approach to sexual and reproductive health, seeing this not just as the absence of disease, but the positive expression of one’s gender, sex and sexuality. Men have substantial sexual and reproductive health needs, including the need for contraception, prevention and treatment of HIV and other sexually transmitted infections (STIs), sexual dysfunction, infertility and male cancers. Yet these needs are often unfulfilled due to a combination of factors, including a lack of service availability, poor health-seeking behaviour among men, health facilities often not considered "male-friendly," and a lack of agreed standards for delivering clinical and preventative services to men and adolescent boys. 

credits: UNFPA
Resource

| 24 September 2017

Global Sexual and Reproductive Health Package for Men and Adolescent Boys

The Global Sexual and Reproductive Health Service Package for Men and Adolescent Boys has been developed to support providers of sexual and reproductive health services. It aims to increase the range and quality of sexual and reproductive services provided that meet the specific and diverse needs of men and adolescents boys. It covers men and adolescent boys in all their diversity, and takes a positive approach to sexual and reproductive health, seeing this not just as the absence of disease, but the positive expression of one’s gender, sex and sexuality. Men have substantial sexual and reproductive health needs, including the need for contraception, prevention and treatment of HIV and other sexually transmitted infections (STIs), sexual dysfunction, infertility and male cancers. Yet these needs are often unfulfilled due to a combination of factors, including a lack of service availability, poor health-seeking behaviour among men, health facilities often not considered "male-friendly," and a lack of agreed standards for delivering clinical and preventative services to men and adolescent boys. 

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

クリニックで順番を待つ患者たち
Resource

| 05 December 2017

Staff and volunteers remain dedicated and determined as the impact of the GGR takes effect

The continuation of many vital health services Amodefa offers in Mozambique are under threat following the reintroduction of the Global Gag Rule by the US Administration. The Global Gag Rule, or Mexico City Policy as it is formally known, stops US aid to all health programmes run by organisations who perform or counsel on abortion. The decision, which will deprive Amodefa of $2 million, 60% of its budget, will have devastating consequences for the fight against HIV in Mozambique, where an estimated 12% of the country’s nearly 30 million population are living with the virus. Photography © IPPF/Grant Lee Neuenburg

クリニックで順番を待つ患者たち
Resource

| 05 December 2017

Staff and volunteers remain dedicated and determined as the impact of the GGR takes effect

The continuation of many vital health services Amodefa offers in Mozambique are under threat following the reintroduction of the Global Gag Rule by the US Administration. The Global Gag Rule, or Mexico City Policy as it is formally known, stops US aid to all health programmes run by organisations who perform or counsel on abortion. The decision, which will deprive Amodefa of $2 million, 60% of its budget, will have devastating consequences for the fight against HIV in Mozambique, where an estimated 12% of the country’s nearly 30 million population are living with the virus. Photography © IPPF/Grant Lee Neuenburg

Young man
Resource

| 01 December 2017

The college student using music to tackle HIV stigma

Compared to many developing countries, HIV prevalence in Nepal is low. Yet there are deep and complex problems around HIV. Stigma remains a huge problem. People living with HIV say they have faced enormous discrimination, including being ostracized by their communities, bullied at school and work, and exposed to insults and even violence.   HIV services and support are central to the work of the Family Planning Association of Nepal (FPAN). Its staff and volunteers run services around the country, providing HIV counselling, education on prevention and treatment, and community home-based care services. People living with HIV are at the forefront of this work: FPAN employs thousands of community home-based care mobilisers who are themselves HIV-positive, meaning they are able to provide people with clear, sensitive and empathetic support that draws on their own experiences.    Photography © IPPF/Jon Spaull  Read Milan's story and watch the video

Young man
Resource

| 01 December 2017

The college student using music to tackle HIV stigma

Compared to many developing countries, HIV prevalence in Nepal is low. Yet there are deep and complex problems around HIV. Stigma remains a huge problem. People living with HIV say they have faced enormous discrimination, including being ostracized by their communities, bullied at school and work, and exposed to insults and even violence.   HIV services and support are central to the work of the Family Planning Association of Nepal (FPAN). Its staff and volunteers run services around the country, providing HIV counselling, education on prevention and treatment, and community home-based care services. People living with HIV are at the forefront of this work: FPAN employs thousands of community home-based care mobilisers who are themselves HIV-positive, meaning they are able to provide people with clear, sensitive and empathetic support that draws on their own experiences.    Photography © IPPF/Jon Spaull  Read Milan's story and watch the video

credits: UNFPA
Resource

| 24 September 2017

Global Sexual and Reproductive Health Package for Men and Adolescent Boys

The Global Sexual and Reproductive Health Service Package for Men and Adolescent Boys has been developed to support providers of sexual and reproductive health services. It aims to increase the range and quality of sexual and reproductive services provided that meet the specific and diverse needs of men and adolescents boys. It covers men and adolescent boys in all their diversity, and takes a positive approach to sexual and reproductive health, seeing this not just as the absence of disease, but the positive expression of one’s gender, sex and sexuality. Men have substantial sexual and reproductive health needs, including the need for contraception, prevention and treatment of HIV and other sexually transmitted infections (STIs), sexual dysfunction, infertility and male cancers. Yet these needs are often unfulfilled due to a combination of factors, including a lack of service availability, poor health-seeking behaviour among men, health facilities often not considered "male-friendly," and a lack of agreed standards for delivering clinical and preventative services to men and adolescent boys. 

credits: UNFPA
Resource

| 24 September 2017

Global Sexual and Reproductive Health Package for Men and Adolescent Boys

The Global Sexual and Reproductive Health Service Package for Men and Adolescent Boys has been developed to support providers of sexual and reproductive health services. It aims to increase the range and quality of sexual and reproductive services provided that meet the specific and diverse needs of men and adolescents boys. It covers men and adolescent boys in all their diversity, and takes a positive approach to sexual and reproductive health, seeing this not just as the absence of disease, but the positive expression of one’s gender, sex and sexuality. Men have substantial sexual and reproductive health needs, including the need for contraception, prevention and treatment of HIV and other sexually transmitted infections (STIs), sexual dysfunction, infertility and male cancers. Yet these needs are often unfulfilled due to a combination of factors, including a lack of service availability, poor health-seeking behaviour among men, health facilities often not considered "male-friendly," and a lack of agreed standards for delivering clinical and preventative services to men and adolescent boys.